Wockhardt Limited
WOCKPHARMA
Clasificación en acciones
#4567
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Precio por acción
$20.68
Capitalización bursátil
$3.36B
Cambio (1 día)
-1.68%
Cambio (1 año)
32.64%
País
IN
Comercio Wockhardt Limited (WOCKPHARMA)
Categoría
Healthcare
Ratio P/B de Wockhardt Limited (WOCKPHARMA)
Ratio P/B al October 2026 TTM: 6.02
Según los informes financieros más recientes y el precio de las acciones de Wockhardt Limited, el ratio P/B actual (TTM) es 6.02. Al final de 2024, el ratio P/B era 2.57.
Historial del ratio P/B de Wockhardt Limited desde 2004 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 6.02 | 16.16% |
| 2025 | 5.18 | 101.34% |
| 2024 | 2.57 | 288.97% |
| 2023 | 0.66 | -19.95% |
| 2022 | 0.83 | -43.97% |
| 2021 | 1.47 | 89.81% |
| 2020 | 0.78 | -61.99% |
| 2019 | 2.04 | -35.21% |
| 2018 | 3.15 | 21.94% |
| 2017 | 2.59 | -14.18% |
| 2016 | 3.01 | -49.76% |
| 2015 | 6.00 | 294.23% |
| 2014 | 1.52 | -82.90% |
| 2013 | 8.90 | 84.07% |
| 2012 | 4.83 | 41.70% |
| 2011 | 3.41 | 72.95% |
| 2010 | 1.97 | 55.55% |
| 2008 | 1.27 | -67.48% |
| 2007 | 3.90 | -0.89% |
| 2006 | 3.93 | -39.11% |
| 2005 | 6.46 | -5.15% |
| 2004 | 6.81 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 3.8424 | -36.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 188.42% |
US
|
